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Abstract
Mutations at codon 641 of EZH2 are recurrent in germinal center B cell lymphomas, and the most common variants lead to
altered EZH2 enzymatic activity and enhanced tri-methylation of histone H3 at lysine 27, a repressive chromatin
modification. As an initial step toward screening patients for cancer genotype-directed therapy, we developed a screening
assay for EZH2 codon 641 mutations amenable for testing formalin-fixed clinical specimens, based on the sensitive SNaPshot
single nucleotide extension technology. We detected EZH2 mutations in 12/55 (22%) follicular lymphomas (FL), 5/35 (14%)
diffuse large B cell lymphomas with a germinal center immunophenotype (GCB-DLBCL), and 2/11 (18%) high grade B cell
lymphomas with concurrent rearrangements of BCL2 and MYC.N oEZH2 mutations were detected in cases of Burkitt
lymphoma (0/23). EZH2 mutations were frequently associated with the presence of BCL2 rearrangement (BCL2-R) in both
the FL (28% of BCL-R cases versus 0% of BCL2-WT cases, p,0.05) and GCB-DLBCL groups (33% of BCL2-R cases versus 4% of
BCL2-WT cases, p,0.04), and across all lymphoma types excluding BL (27% of BCL2-R cases versus 3% of BCL2-WT cases,
p,0.003). We confirmed gain-of-function activity for all previously reported EZH2 codon 641 mutation variants. Our findings
suggest that EZH2 mutations constitute an additional genetic ‘‘hit’’ in many BCL2-rearranged germinal center B cell
lymphomas. Our work may be helpful in the selection of lymphoma patients for future trials of pharmacologic agents
targeting EZH2 and EZH2-regulated pathways.
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Introduction
Human mature B cell lymphomas encompass a diverse
spectrum of biologically and clinically distinct entities, many of
which appear to recapitulate a specific stage of B cell development
by morphologic, immunophenotypic and/or gene expression
criteria. Follicular lymphoma (FL), Burkitt lymphoma (BL), and
a gene expression-defined subset of diffuse large B cell lymphoma
(germinal center B cell-phenotype diffuse large B cell lymphoma,
or GCB-DLBCL) all recapitulate biological features of normal
germinal center B cells. [1,2] As new discoveries have improved
our understanding of the genetics and phenotypic characteristics of
B cell lymphomas, it has become clear that some oncogenic
mutations occur with increased frequency, or even exclusively, in
lymphomas of a certain phenotype. One prominent example is the
t(14;18)(q32;q21) IGH-BCL2 rearrangement, which leads to
overexpression of the Bcl-2 oncoprotein, and is frequently present
in follicular lymphoma and GCB-DLBCL, but not in other gene
expression-defined subtypes of DLBCL. [3]
EZH2 encodes the enzymatic subunit of the polycomb repressive
complex 2 (PRC2), which mediates gene repression through
trimethylation of histone H3 at lysine 27 (H3K27). Point mutations
affecting codon 641 of EZH2 were recently described in a subset of
GCB-DLBCL and FL, [4] but were absent from activated B cell-
phenotype DLBCL (ABC-DLBCL), small lymphocytic lymphoma,
mantle cell lymphoma, and peripheral T cell lymphoma, all of
which lack a germinal center phenotype. Lymphoma-associated
mutations affecting EZH2 were initially reported to result in
enzymatic loss-of-function based on in vitro studies which used
unmodified histone tails as a substrate for modification by
recombinant PRC2 complexes, but the most common variants
have subsequently been shown to possess increased activity in
trimethylation of H3K27 in the mono- or di-methylated state. [5,6]
Overexpression and hyperactivity of EZH2 have been implicated in
the pathogenesis of several cancer types, including prostate, [7,8]
breast, and endometrial carcinomas, as well as melanoma. [9] The
discovery that EZH2 is a mutant oncogene in germinal center-
phenotype B cell lymphomas raises the possibility of targeting this
pathway pharmacologically in the treatment of patients with these
lymphomas. Important steps toward this goal include further
delineation of the lymphoma types in which this mutation occurs,
and development of assays amenable to detection of these mutations
in routine clinical specimens.
PLoS ONE | www.plosone.org 1 December 2011 | Volume 6 | Issue 12 | e28585In this study, we report the results of testing for EZH2 codon
641 mutations in a large series of B cell lymphomas of germinal
center origin, using a sensitive and specific single nucleotide
extension method (SNaPshot) which has been validated for clinical
tumor genotyping at our institution. We detect EZH2 mutations in
a significant proportion of BCL2-rearranged follicular lymphomas,
BCL2-rearranged diffuse large B cell lymphomas, and high-grade
B cell lymphomas with concurrent BCL2 and MYC rearrange-
ments (so-called ‘‘double-hit lymphomas’’), but not in BL. The
data suggest that this mutation is not universally present in all
germinal center-phenotype B cell lymphoma subtypes but appears
to correlate with BCL2 status. Finally, we provide evidence that all
previously reported EZH2 codon 641 mutation variants show the
potential for enhanced H3K27 trimethylation activity.
Materials and Methods
Ethics statement
All research was conducted with the written approval of the
Partners Healthcare Human Research Committee in accordance
with the Ethical Principles and Guidelines for the Protection of
Human Subjects of Research, generally known as the ‘‘Belmont
Report.’’
Case selection
Cases of FL, GCB-DLBCL, MYC and BCL2 rearranged
‘‘double hit’’ lymphomas (DHL), and BL were identified from
our pathology archives. All cases were diagnosed according to
WHO 2008 criteria, and cases of uncertain classification were
reviewed by a panel of expert hematopathologists (A.R.S., L.R.Z.,
J.A.F., and N.L.H.). The follicular lymphoma cohort was enriched
for cases of low morphologic grade and a Ki-67 proliferation index
(PI) .30%, which prior work has suggested may represent a
distinct poor prognosis subgroup. [10] GCB-DLBCL cases were
identified on the basis of tumor expression of either CD10 or Bcl-6
without Mum-1. [11] DHL cases were classified as DLBCL or
intermediate between DLBCL and BL by WHO 2008 criteria, but
were analyzed as one unique group for this study.
Immunohistochemistry
Immunohistochemistry, including stains for CD10, Bcl-6,
Mum-1, and Ki-67, was performed using protocols and antibodies
validated for clinical use as described previously. [12]
DNA extraction
Areas showing at least 40% malignant cells on hematoxylin and
eosin (H&E) or immunohistochemically stained slides were
selected for coring (1.5 mm) of the respective formalin-fixed,
paraffin-embedded (FFPE) tissue blocks. Total nucleic acid (TNA)
was purified using the FormaPure method (Agencourt, Danvers,
MA), which was automated on a Beckman Biomek II liquid
handler (Beckman Coulter, Brea, CA).
SNaPshot genotyping
Our institution routinely uses the SNaPshot multiplex single-
nucleotide extension assay for clinical genotyping of tumor-
associated point mutations. [13] We designed polymerase chain
reaction (PCR) and SNaPshot extension primers to redundantly
genotype the first two nucleotides of EZH2 codon 641 in both the
forward and reverse direction, a strategy that can detect all
possible single point mutations leading to a missense substitution at
that codon. Following initial validation we applied this assay to
124 cases of B cell lymphoma with a germinal center phenotype.
SNaPshot genotyping was performed in 96-well plates and is
based on a one-tube protocol validated for clinical use in the
Massachusetts General Hospital Diagnostic Molecular Pathology
Laboratory. Genomic DNA containing EZH2 codon 641 was
PCR amplified from TNA using the forward primer 59-
AGTTAGTATATACAATGCCACCTG-39 and reverse primer
59- CTCTAGCATCTATTGCTGGC-39, followed by a cleanup
reaction with shrimp acid phosphatase and exonuclease 1 (USB).
The SNaPshot single-nucleotide extension reaction was performed
using SNaPshot Ready Reaction mix (Applied Biosystems, Foster
City, CA) and 4 multiplexed extension primers designed to
interrogate the first two nucleotides of EZH2 codon 641 on both
the coding and noncoding strands. Following a final shrimp acid
phosphatase cleanup reaction, extension products were evaluated
by capillary electrophoresis, using an Applied Biosystems 35006L
Genetic Analyzer. Extension primers used for initial screening of
all samples were as follows:
EZH2_c.1921F.v1: 59-ACTGACTGCAGAAAAATGAATT-
CATCTCAGAA-39
EZH2_c.1922F.v1: 59-GACTGACTGACTGACTGACTGA-
CTGACTGCAGAAAAATGAATTCATCTCAGAAT-39
EZH2_c.1921R.v1: 59-GACTGACTGACTGACTGACTGA-
CTGTGCCTTACCTCTCCACAGT-39
EZH2c.1922R.v1: 59-AGTGCCTTACCTCTCCACAG-39
A final set of optimized extension primers was used to confirm
all detected mutations:
EZH2_c.1921F.v2: 59-CAGAAAAATGAATTCATCTCAGAA-
39
EZH2_c.1922F.v2: 59-AGTCAGTCAGTCAGAAAAATGA-
ATTCATCTCAGAAT-39
EZH2_c.1921R.v2: 59-AGTCAGTCAGTCAGTCAGTCAG-
TCAGGTGCCTTACCTCTCCACAGT-39
EZH2_c.1922R.v2: 59-AGTCAGTCAGTCAGTCAGTCAGT-
CAGTCAGTCAGTCAGTGCCTTACCTCTCCACAG-39
All transcript sequence references are to the EZH2 coding
sequence of RefSeq isoform C, NM_001203247.1, as explained
subsequently.
Fluorescence in-situ hybridization
All cases of unknown BCL2 status were assessed for the presence
of BCL2 rearrangement on 2–5 micron FFPE sections using the
Vysis LSI BCL2 Dual Color Break Apart Rearrangement Probe
(Abbott Molecular, Des Plaines, IL). Cases were scored as BCL2-
rearranged (BCL2-R) on the basis of detecting unambiguous probe
separation or splitting in at least 15% of observed cells (50-cell
count) as scored by two independent observers (M.N. and
R.J.H.R.).
Statistical analysis
Statistical significance of differences in EZH2 mutation
frequency between lymphoma groups was calculated by the two-
tailed Fisher’s exact test using GraphPad QuickCalcs (GraphPad
Software Inc., La Jolla, CA). Statistical significance was defined as
p,0.05.
Cloning of EZH2 coding sequence
The EZH2 coding sequence was PCR amplified from pooled
human bone marrow cDNA (Clontech) using the primers 59-
GGGGACAAGTTTGTACAAAAAAGCAGGCTGCACCAT-
GGACTACAAGGACGACGATGACAAAGGCCAGACTGG-
GAAG-39 and 59-GGGGACCACTTTGTACAAGAAAGCT-
GGGTTAAGGCAGCTGTTTCAGAGG-39 which encode an
N-terminal FLAG tag. PCR products were cloned into
pDONR221 and confirmed by sequencing. A clone matching
EZH2 Mutations in B Cell Lymphomas
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into pCDNA3.2/V5-DEST using the Gateway recombination
system (Invitrogen). Codon 641 and 689 point mutations were
generated in pENTRY vectors using the QuickChange Lightning
kit (Stratagene) and were subcloned into pCDNA3.2/V5-DEST.
SET domain-truncated EZH2 (EZH2DSET) was generated by
PCR subcloning with the C-terminal primer 59-GGGGAC-
CACTTTGTACAAGAAAGCTGGGTTCATGCCAGCAATA-
GATGCTTTTT-39 as previously described. [7]
EZH2 transgene expression and western blotting
EZH2 vectors were transfected into sub-confluent NIH-3T3
murine fibroblasts with Fugene HD reagent (Roche) according to
the manufacturer’s instructions. Cells were harvested 72 hours
later and conventional western blotting was performed on whole-
cell extracts (targets: EZH2, Beta-actin), or acid-extracted histones
(targets: total H3, H3K27me3, H3K27me2, H3K27me1,
H3K9me3). Ponceau S was used to confirm transfer of equivalent
total protein levels in all lanes prior to antibody binding. The
antibodies used for western blot are as follows:
Beta-actin – Abcam (Cambridge, MA), Cat# ab8827 (rabbit)
EZH2 – Active Motif (Carlsbad, CA), Cat# 39639 (rabbit)
H3 (total) – Abcam, Cat# ab1791 (rabbit)
H3K9me3 – Abcam, Cat# ab8898 (rabbit)
H3K27me1 – Active Motif, Cat# 39377 (rabbit)
H3K27me2 – Abcam, Cat# ab24684 (rabbit)
H3K27me3 – Millipore (Billerica, MA), Cat# 07-449 (rabbit)
RNA-seq analysis
Published RNA-seq data for DLBCL cell lines Oci-Ly1, Oci-
Ly7, and Oci-Ly19 (SRA accession SRP001599) [14] were aligned
to the human genome (Hg19) using TopHat [15] and analyzed
with the Integrative Genomics Viewer. [16]
Results
The results of SNaPshot genotyping in 124 germinal center B
cell lymphomas are shown in Table 1. Overall, we detected EZH2
codon 641 mutations in 19/124 (15%) cases. All mutations were
genotyped redundantly by the corresponding forward and reverse
extension primers, and were detected in independent screening
and confirmatory runs. Detected mutations included all of the four
most common reported variants (Figure 1). No novel mutations
were identified.
The frequency of EZH2 mutations within the various
lymphoma subtypes is given in Table 1. Among the cases
screened, EZH2 mutations were detected with relatively high
frequency in FL (12/55, 22%). There was no difference in EZH2
mutation frequency between the low-PI and high-PI subgroups of
grade 1–2 FL (low PI 7/23, 30%; high PI 4/18, 22%, p=0.73) or
between EZH2 mutation status and morphologic FL grade (Grade
1–2 11/41, 27%; Grade 3 1/14, 7%, p=0.16). Within the grade 3
FL group, 3 cases were graded as 3B, and none of these cases
showed an EZH2 mutation. We also detected EZH2 mutations in
the GCB-DLBCL (5/35, 14%) and DHL (2/11, 18%) groups, but
not in any case of BL (0/23). Four of the five DLBCL EZH2
mutations belonged to a group of nine DLBCL cases that had
concurrent diagnoses of grade 3 FL.
We used FISH to screen for BCL2 rearrangements in all of our
lymphoma cases that were not previously tested for this aberration.
As expected, BCL2 rearrangements were detected in the majority
of FL (78%) and in a smaller proportion of GCB-DLBCL (34%)
(Table 1). We found these mutations to occur more frequently in
BCL2-rearranged lymphomas than in lymphomas lacking a BCL2
rearrangement. The increased frequency of EZH2 mutations was
statistically significant in the FL group (28% of BCL2-R cases
versus 0% of BCL2-WT cases, p,0.05), the DLBCL group (33%
of BCL-R cases versus 4% of BCL2-WT cases, p,0.04), and
across all lymphoma types excluding BL, which universally lacked
both BCL2 rearrangements and EZH2 mutations (27% of BCL2-R
cases versus 3% of BCL2-WT cases, p,0.003) (Figure 2).
To determine the function of lymphoma-associated EZH2
mutations in a cellular context, we PCR cloned the EZH2 coding
sequence from human bone marrow cDNA. Of the 7 independent
clones we sequenced, all contained the exon 8–9 splice junction
seen in EZH2 Refseq isoform C (NM_001203247), corresponding
to the Y641 codon designation used in the initial description of the
lymphoma mutation, [4] while no clones contained the exon 8–9
splice junction seen in the slightly longer EZH2 Refseq isoform A
(NM_004456), which has been used as a reference transcript in
some later work, resulting in designation of the same residue as
Y646. [17,14] Alignment of published RNA-seq data for GCB-
DLBCL cell lines Oci-Ly1, Oci-Ly7, and Oci-Ly19 demonstrated
that the vast majority of reads spanning the EZH2 exon 8–9 splice
junction support the splice junction found in isoform C, and not
the junction found in isoform A (Figure S1 and data not shown).
Of the available spliced expressed sequence tags (ESTs) in
GenBank (release 185.0, accessed August 30, 2011) derived from
various tissues, 39/41 sequences match the exon 8–9 splice
junction found in isoform C.
We generated expression vectors encoding wild-type EZH2,
each of the five reported lymphoma-associated codon 641
mutants, and two well-characterized synthetic methyltransferase
loss-of-function mutants, the point mutant H689A, [18] and a
truncation mutant lacking the C-terminal methyltransferase (SET)
domain. Western blotting of acid-extracted histones from
transiently transfected NIH-3T3 fibroblasts showed no difference
in global H3K27me3 levels between cells transfected with empty
vector, wild-type EZH2, EZH2DSET (Figure 3), or EZH2 H689A
(data not shown). In contrast, there was a marked increase in
global H3K27me3 levels in cells transfected with each of the five
lymphoma-associated mutants. There was no measurable differ-
ence in global levels of H3K27me2, H3K27me1, and H3K9me3
between the transfectants (Figure S2).
Discussion
Our findings confirm and extend prior work regarding the
prevalence of EZH2 mutations in B cell lymphomas and the
molecular function of these mutations. Clinical detection of
oncogenic point mutations conferring enzymatic gain-of-function
has been a fruitful strategy for triaging patients to molecularly
targeted therapy in several cancer types, including lung adeno-
carcinoma (EGFR mutations) [19] and melanoma (BRAF V600E
mutations). [20] While specific small-molecule inhibitors of EZH2
are not yet clinically available, there is ongoing interest in the
development of such agents. [5] Our SNaPshot-based assay
reproducibly detected EZH2 mutations in a substantial proportion
of germinal center lymphomas from routine FFPE clinical
specimens. The absence of EZH2 mutations in BL highlights both
the biological specificity of the EZH2 codon 641 mutation for
certain lymphoma subtypes, and the technical specificity of our
assay.
In comparison to prior studies, we detected a relatively high rate
of EZH2 mutations in FL (22% overall and 27% in the common
grade 1–2 subtype) compared to prior reports (7% [4] and 12%
[21] overall). This may be due, in part, to the higher sensitivity of
SNaPshot compared to Sanger (chain terminator) sequencing for
EZH2 Mutations in B Cell Lymphomas
PLoS ONE | www.plosone.org 3 December 2011 | Volume 6 | Issue 12 | e28585Figure 1. SNaPshot detection of EZH2 codon 641 mutations. A: Representative electropherograms for SNaPshot genotyping of EZH2 in B cell
lymphomas. Five representative tracings are shown, representing lymphomas with wild-type EZH2 codon 641 and each of the four distinct missense
substitutions detected in this study. Two complementary mutant peaks (arrows) appear in each mutant sample, corresponding to detection of the
missense substitution by both the forward and reverse primers at the same nucleotide position. B: Distribution of EZH2 codon 641 missense
mutations detected by SNaPshot.
doi:10.1371/journal.pone.0028585.g001
Table 1. EZH2 and BCL2 aberrations in germinal center lymphomas by category.
Classification EZH2 mutated BCL2 rearranged
All follicular lymphoma (n=55) 12 (22%) 43 (78%)
Grade 1–2, low PI (n=23) 7 (30%) 21 (91%)
Grade 1–2, high PI (n=18) 4 (22%) 15 (83%)
Grade 3 (n=14)* 1 (7%) 7 (50%)
All GCB-DLBCL (n=35) 5 (14%) 12 (34%)
Pure DLBCL, no prior lymphoma (n=23)** 1 (4%) 6 (26%)
Concurrent DLBCL and grade 3 FL (n=9) 4 (44%) 4 (44%)
Prior low-grade FL (n=1) 0 (0%) 1 (100%)
Prior low-grade lymphoma, not FL (n=2) 0 (0%) 1 (50%)
‘‘Double hit’’ B cell lymphomas (n=11)*** 2 (18%) 11 (100%)
De novo (n=7) 1 (14%) 7 (100%)
History of follicular lymphoma (n=4) 1 (25%) 4 (100%)
Burkitt lymphoma (n=23) 0 (0%) 0 (0%)
*Includes grades 3A (n=11) and 3B (n=3). All grade 3B cases lacked both EZH2 mutation and BCL2 rearrangement.
**A single case within this group lacking both an EZH2 mutation and a BCL2 rearrangement had concurrent follicular lymphoma in situ.
***All ‘‘double hit’’ B cell lymphomas had rearrangements of the MYC and BCL2 loci.
doi:10.1371/journal.pone.0028585.t001
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results are consistent with those of a recent study which used deep-
sequencing techniques (genome, exome, and RNA sequencing) on
a small number of follicular lymphomas and reported EZH2
mutations in 4/13 cases (31%). [14] Thus, the true rate of EZH2
mutations in follicular lymphoma may be higher than originally
reported. EZH2 mutations were not enriched in more proliferative
subgroups of FL (low grade/high PI FL and grade 3 FL),
suggesting that EZH2 mutations are not associated with known
aggressive subtypes of FL. Larger studies with clinical follow-up
will be required to determine whether this mutation carries
independent prognostic significance in FL.
In contrast to the findings in FL, we detected mutations in a
relatively low proportion of GCB-DLBCL (14%) compared to the
original report (22%) [4]. Our use of an immunophenotypic
surrogate for the GCB-DLBCL gene expression profile could
partly explain this discrepancy, although our findings are similar to
those of another recent study, which found EZH2 mutations in
14% of a cohort of 63 microarray-defined GCB-DLBCL. [22]
Interestingly four of the five EZH2 mutations detected in the
GCB-DLBCL cohort occurred in a subgroup of nine cases in
which the diagnostic biopsy showed a large cell lymphoma with
areas of both follicular and diffuse growth, resulting in concurrent
diagnoses of DLBCL and grade 3 FL by current WHO criteria.
[1] None of these nine patients had a prior history of follicular
lymphoma, and these cases appear to represent de novo high-grade
germinal center phenotype lymphomas with partial residual
folliculotropism. This finding raises the possibility that EZH2-
mutated DLBCL may have characteristic morphological and
biological features, and merits further investigation.
The EZH2 codon 641 mutation was first identified through
whole-genome sequencing of a follicular lymphoma that lacked a
t(14;18) IGH-BCL2 rearrangement. [4] However, we found
frequent, though not universal, co-occurrence of EZH2 codon
641 mutations with rearrangements of BCL2. This implies that
EZH2 mutations do not substitute for BCL2 rearrangement, but
rather represent a functionally distinct oncogenic ‘‘hit’’ in germinal
center B cell lymphomagenesis. Targeted inhibitors of BCL2 have
been developed, with some advancing into clinical trials. [23] Our
finding that many lymphomas show oncogenic activation of both
BCL2 and EZH2 raises the possibility that combined BCL2 and
EZH2 inhibition may represent a potential therapeutic strategy for
many patients.
BL is a prototypical germinal center-derived lymphoma, but
shows substantial biologic, pathogenic, and epidemiologic differ-
ences from FL and DLBCL. [1] Our findings suggest that EZH2
mutations are rare or absent in this lymphoma type. We did detect
EZH2 mutations in MYC and BCL2-rearranged ‘‘double hit’’ high
grade B cell lymphomas, which often show morphologic, genetic,
and immunophenotypic features intermediate between DLBCL
Figure 2. Frequency of EZH2 mutations in germinal center
lymphomas by BCL2 status. Within each class of germinal center
lymphoma, EZH2 mutations were significantly more frequent in cases
with rearrangements of BCL2. Burkitt lymphoma (not shown) universally
lacked both aberrations. The two total columns at right include all
lymphomas in the study (fourth column) or all lymphomas except BL
(fifth column) – see table 1 for subtype distribution. Abbreviations:
FL=follicular lymphoma, GCB-DLBCL=germinal center B-cell pheno-
type diffuse large B-cell lymphoma, DHL=‘‘double hit’’ high-grade B-
cell lymphoma (MYC and BCL2 rearranged), BL=Burkitt lymphoma.
doi:10.1371/journal.pone.0028585.g002
Figure 3. Western blot of mutant EZH2 expression in NIH-3T3 fibroblasts. Transgenic expression of vectors encoding lymphoma-associated
EZH2 codon 641 mutants, but not wild-type or SET domain-truncated (DSET) EZH2, leads to a consistent increase in global trimethylation of H3K27
compared to vector control. Western blot antibodies are listed on the right. Ponceau S depicts total protein at ,15 kDa on acid-extract blots.
doi:10.1371/journal.pone.0028585.g003
EZH2 Mutations in B Cell Lymphomas
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integrative studies including gene expression profiling have
suggested that the relative paucity of large-scale genomic
imbalances (‘‘genetic complexity’’) can be helpful in distinguishing
‘‘true’’ BL from other high-grade B cell lymphomas. [24] Our
results suggest that EZH2 mutation status could also potentially
contribute to this distinction.
The results of our mutant EZH2 expression experiments
indicate that the mutant protein conferred a gain-of-function
phenotype as evidenced by increased generation of the
H3K27me3 histone mark, the mechanism of which has been
demonstrated by others. [5] Interestingly, the mutation that was
most common in our series, Y641N, was estimated to be the most
potent of the four common mutations at generating H3K27me3 in
the heterozygous state, based on in-vivo enzyme kinetics, [5] while
Y641H, the least common mutation in our series, was predicted to
be least potent. These results suggest that more potent mutations
may undergo stronger oncogenic selection. Our novel demonstra-
tion of a similar gain-of-function activity for the Y641C mutant in
an overexpression assay is consistent with the reported occurrence
of this mutation in B cell lymphoma, [4] in which most EZH2
mutations are thought to confer gain-of-function. However, the
Y641C mutation has also been reported in an acute myeloid
leukemia cell line, despite the fact that many reported EZH2
mutations in myeloid tumors are clearly inactivating. [17] These
findings suggest the possibility of a more complex function for
some myeloid EZH2 mutations, and highlight the need for further
functional investigation of these mutant proteins. While the
H3K27me3 modification is known to have a repressive effect on
gene expression, the precise genomic targets that are affected by
the mutant protein during lymphomagenesis and confer selective
advantage have not been identified.
For our transgenic work, we used a cDNA clone for EZH2 with
a coding sequence matching that of the original reported EZH2
coding sequence [25] and EZH2 Refseq isoform C
(NM_001203247). Our results suggest that this is the predominant
long splice form of EZH2 in lymphoma and other tissues, and for
this reason we prefer to designate the EZH2 codon affected by
recurrent mutations in B cell lymphoma as Y641, rather than
Y646. Shorter EZH2 transcripts produced by variant splicing of
exons 3 and 4 are also well supported by ESTs and other public
data, and are of uncertain significance.
In conclusion, we have developed a clinically applicable assay
for sensitive detection of EZH2 codon 641 mutations in FFPE
tissue, and demonstrate frequent occurrence of these gain-of-
function mutations in the full biological spectrum of BCL2-
rearranged germinal center phenotype B cell lymphomas, but not
in Burkitt lymphoma.
Supporting Information
Figure S1 RNA-seq analysis of EZH2 transcript splice variants
in the DLBCL cell line Oci-Ly1. Alignment of RNA-seq data from
the DLBCL cell line Oci-Ly-1 [14] to the 39 splice junction of
EZH2 exon 8 shows that the vast majority of transcripts contain
the splice junction seen in EZH2 isoform C (NM-001203247), as
marked by the black arrow. Only rare reads, marked with a red
arrow, support the alternate splice site seen in EZH2 isoform A
(NM_004456), which encodes an additional 5 amino acids.
Findings in the DLBCL cell lines Oci-Ly7 and Oci-Ly19 (not
shown) were similar.
(TIF)
Figure S2 Western blot of EZH2 mutant overexpression in
NIH-3T3 fibroblasts. Transgenic overexpression of lymphoma-
associated EZH2 codon 641 mutants was not associated with
differences in the global levels of histone marks H3K27me1,
H3K27me2, and H3K9me3 compared to vector control, wild-
type, or SET domain-inactivated EZH2.
(TIF)
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